In contrast, other drug targets (APOC3, NPC1L1, PCSK9, APOB, CETP, LDLR and LPL) exhibited neutral effects on osteonecrosis outcomes based on their genetic resemblances (Figure 2C,D). This evidence concerns the gene LPL and osteonecrosis.